Regulation A+ Offering: Epilog Imaging Files a Form 1-A
Epilog Imaging Systems filed a Form 1-A for a Regulation A+ offering of up to 10 million non-voting shares at $3.00 each; here are the terms and the risks.
- Filer
- Epilog Imaging Systems, Inc.
- Form
- 1-A
- CIK
- 1783128
- On EDGAR
- 0001477932-26-006383

A Regulation A+ offering is a public securities offering that lets a smaller company raise capital under an SEC exemption, using a Form 1-A offering statement instead of a full registration. Epilog Imaging Systems, Inc., an AI vision company based in San Jose, California, filed one on Oct. 21, 2026.
What happened
The preliminary offering circular, dated Oct. 21, 2026, covers up to 10,000,000 shares of non-voting common stock. Of those, 8,333,333 shares are for sale for cash: up to 8,000,000 from the company and up to 333,333 from selling securityholders. The remaining 1,666,667 are bonus shares the company would issue to eligible investors. The price is $3.00 a share, the minimum investment is 333 shares ($999), and buyers also pay a 3.0% transaction fee.
The offering has no minimum amount and no third-party escrow. Subscriptions run through a platform managed by DealMaker Securities, LLC, which acts as broker-dealer of record for administrative and compliance functions and would receive a 4.5% commission on cash collected, plus other listed fees. The company says that if it sold the full $25 million remaining under its annual limit, net proceeds would be about $22.2 million after roughly $2.5 million of offering expenses. The circular states that nothing can be sold until the SEC qualifies the offering statement.
How it works
Epilog describes itself as a Tier 2 issuer. Tier 2 allows offerings of up to $75 million in a 12-month period under Rule 251(a)(2), and the circular counts the full $30.75 million value of this offering, including the bonus shares, against that cap. A qualified Tier 2 issuer must file ongoing reports, and the circular says the company will file a post-qualification amendment with updated financials at least every 12 months while the offering continues.
Bonus shares can equal up to 20% of the shares an investor buys, according to eligibility criteria in the plan of distribution. The circular warns that investors who do not qualify for the full bonus face more dilution than those who do.
Key terms
- Preliminary offering circular: the disclosure document filed before qualification; terms can change.
- Selling securityholders: existing holders selling alongside the company, about 4% of each share sold, with proceeds going to them.
- Qualification: the SEC step that allows sales to begin, comparable to effectiveness for a registered offering.
The business and the risks
The company builds AI vision devices that run at the edge. Its products include SideCar, a retrofit driver-assistance system, plus Vortex and CloseView vision-forensics products sold through its Aperis AI subsidiary, and Wellcome, a patented contactless health-screening system. It was incorporated in Delaware in 2010 as Biotronix Corporation and renamed in 2015.
The financial statements carry a going-concern warning. At Dec. 31, 2025, the company had an accumulated deficit of $5,761,555, a 2025 net loss of $945,765 and cash used in operations of $940,247. For the six months ended June 30, 2026, net loss was $1,951,750, compared with $166,582 a year earlier, and total equity was $1,265,704.
FAQ
Can anyone invest now? No. Sales cannot occur until qualification.
Is it listed on an exchange? No. The circular says there is no established public trading market for the non-voting common stock, and investors buy through the offering platform. It refers only to a possible future Nasdaq listing.
Why does the going-concern language matter? The financial statements disclose substantial doubt that the company can continue operating without outside financing, so the outcome of this raise bears on its survival.
Prepared with AI assistance from the documents listed in the margin and reviewed under our editorial policy. Not investment advice.